Sanjay Kaul, MD
July 26th, 2010
Questions for Sanjay Kaul about TIDE and Avandia
Sanjay Kaul, MD and Harlan M. Krumholz, MD, SM
CardioExchange’s editor-in-chief Harlan Krumholz discussed the TIDE trial on email with Sanjay Kaul, who was a member of the FDA’s advisory panel last week on Avandia. Here is a lightly edited version of their exchange. Krumholz: What is your response to the FDA announcement that it has placed TIDE on a “partial clinical hold”? Do you […]
March 3rd, 2010
Rosiglitazone: When Evidence Is Inconclusive Even After FDA Approval
Sanjay Kaul, MD
We welcome Sanjay Kaul, MD, lead author of a recent American Heart Association/American College of Cardiology science advisory about the cardiovascular risks of thiazolidinedione drugs, to answer our questions about rosiglitazone. We encourage you to ask yours. You and your coauthors call the evidence on the cardiovascular risks of rosiglitazone “inconclusive.” When you prescribe a […]
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?